CICC Raises China Medical System Target 6% to HK$17.50

Edgen Stock·Mar 18 2026, 04:50

Share to

Share to

Copy link

Key Takeaways

Investment bank CICC raised its price target on China Medical System (00867.HK) by 6% to HK$17.50, citing a successful strategic shift towards innovative drugs. The upgrade follows 2025 results that met expectations and significant progress in the company's product pipeline, particularly in high-growth specialty areas.

Analyst Upgrade: CICC reiterated its "Outperform" rating and lifted its target price to HK$17.50, implying 35% potential upside from the current price.
Growth Engines: The skin health business saw revenues expand 73.2% to 1.07 billion yuan, while the innovative and exclusive drugs segment grew 44.1%, now representing nearly 60% of pharmaceutical sales.
Pipeline Momentum: The company secured key approvals for its vitiligo cream and renal anemia drug in early 2026 and is advancing its skin health subsidiary, Dermavon, towards a separate listing on the Hong Kong Stock Exchange.

CICC Boosts Target 6% on Strong 2025 Performance

Investment bank CICC reaffirmed its bullish outlook on China Medical System (00867.HK) on March 18, maintaining an "Outperform" rating and raising its price target by 6% to HK$17.50. The new target implies a 35% upside and values the company at 18.0 times its estimated 2026 earnings. The revision comes after the pharmaceutical firm reported 2025 results that aligned with market expectations, posting total revenue of 8.21 billion yuan, a 9.9% year-over-year increase, and an adjusted net profit of 1.78 billion yuan.

The analysis highlights a successful structural shift, with sales from innovative and exclusive drugs becoming the primary growth driver. This segment's revenue climbed 23.3% to 5.61 billion yuan, now accounting for 59.8% of total drug sales, an increase of 7.0 percentage points from the previous year. This performance indicates the company has largely overcome the impact of China's national volume-based procurement policies.

Skin Health Unit Powers 73% Growth Ahead of IPO

A key factor in CICC's optimistic forecast is the explosive growth of China Medical System's specialized divisions, particularly its skin health business. The unit's revenue expanded 73.2% year-over-year in 2025 to 1.07 billion yuan. This growth is underpinned by the rapid commercialization of its innovative vitiligo treatment, Ruxolitinib Phosphate Cream (Lumirix®), which received its drug registration certificate on January 30, 2026, and began issuing prescriptions across China in less than two months. CICC anticipates the drug could achieve at least 500 million yuan in sales in 2026.

The company plans to capitalize on this momentum by spinning off its skin health subsidiary, Dermavon, for a separate listing on the Hong Kong Stock Exchange. This move is expected to unlock value for shareholders and provide dedicated capital for the high-growth dermatology franchise. Other specialty lines also performed well, with the ophthalmology business growing 12.9%.

New Drug Approvals Fortify R&D Pipeline

China Medical System is significantly scaling its innovation efforts, with R&D expenditures increasing by 40.5% in 2025 to 1.06 billion yuan. This investment is yielding tangible results, strengthening the company's product pipeline. On March 13, 2026, the company announced its new drug for renal anemia, Desidustat Tablets, was approved for marketing in China by the National Medical Products Administration.

This approval, along with the launch of the vitiligo cream, is part of a broader pipeline maturation. In 2025, the company achieved two new drug approvals, filed six New Drug Applications (NDAs), and received six Investigational New Drug (IND) approvals. A self-developed siRNA drug targeting INHBE, CMS-D008, also secured an IND in March 2026, showcasing progress in its in-house R&D capabilities.